SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates

Company Performance - SOPHiA GENETICS reported a quarterly loss of $0.26 per share, which was worse than the Zacks Consensus Estimate of a loss of$0.21, representing an earnings surprise of -23.81% [1] - The company posted revenues of $17.78 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 7.30$15.78 million in the same quarter last year [2] - Over the last four quarters, SOPHiA GENETICS has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Market Outlook - SOPHiA GENETICS shares have increased by approximately 2.3% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.20 on revenues of$17.85 million, and for the current fiscal year, it is -$0.80 on revenues of$74.18 million [7] Industry Context - The Medical Info Systems industry, to which SOPHiA GENETICS belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for SOPHiA GENETICS is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]